<DOC>
	<DOCNO>NCT01372878</DOCNO>
	<brief_summary>This study design establish effectiveness PillCam® Platform PillCam® COLON 2 capsule demonstrate identification subject polyps compare optical colonoscopy .</brief_summary>
	<brief_title>Evaluation Capsule Endoscopy With PillCam® COLON 2 Visualization Colon</brief_title>
	<detailed_description>This multi-center study design evaluate safety effectiveness PillCam Platform PillCam COLON 2 capsule demonstrate identification subject polyps , compare optical colonoscopy . 884 subject participate study . All subject enrol study indicate schedule undergo colonoscopy base age demographic screen polyp . Each subject require follow bowel preparation regimen undergo capsule endoscopy ( CE ) follow optical colonoscopy ( OC ) . The optical colonoscopy procedure schedule 4-6 week CE procedure allow central reader read PillCam RAPID video . The colonoscopist keep blinded CE result</detailed_description>
	<criteria>1 . Subject 50 75 year age , classified average risk per AGA Guidelines CRC Screening . 2 . Subject received explanation nature study agree provide write informed consent . 1 . Subject history colorectal cancer 2 . Subjects history positive colon assessment ( include CT , optical colonoscopy , sigmoidoscopy etc . ) 3 . Subject history negative colon assessment ( include CT , optical colonoscopy , sigmoidoscopy etc . ) &lt; 5 year subject would define require screen time frame 4 . Subject first degree relative diagnose colorectal cancer age 60 year old 2 ( ) first degree relative diagnose colorectal cancer age . 5 . Subject suspect diagnosed familial adenomatous polyposis , hereditary non polyposis colon cancer , high risk genetic syndrome . 6 . Subject suspect diagnosed inflammatory bowel disease , chronic ulcerative colitis Crohn 's disease . 7 . Subject suspect diagnosed hematochezia , melena , Fe deficiency anemia rectal bleeding , include positive FOBT test variety . 8 . Subject suspect diagnosed bowel obstruction . 9 . Subject dysphagia swallow disorder . 10 . Subject congestive heart failure . 11 . Subject Type 1 Type II Diabetes . 12 . Subject prior abdominal surgery gastrointestinal tract last 6 month , uncomplicated procedure would unlikely lead bowel obstruction base clinical judgment investigator . 13 . Subject cardiac pacemaker implant electro medical device . 14 . Subject allergy know contraindication medication use study . 15 . Subject expect undergo MRI examination within 7 day ingestion capsule . 16 . Subject condition believe increase risk capsule retention intestinal tumor , radiation enteritis , incomplete colonoscopy due obstruction NSAID enteropathy . 17 . Subject stricture , fistula and/or chronic constipation . 18 . Subject history clinical evidence renal disease and/or previous clinically significant laboratory abnormality renal function parameter . 19 . Subject know gastrointestinal motility disorder . 20 . Subject know delayed gastric empty . 21 . Subject condition , preclude compliance study and/or device instruction . 22 . Women either pregnant nursing time screening , childbearing potential practice medically acceptable method contraception . 23 . Subject suffers life threaten condition . 24 . Concurrent participation another clinical trial use investigational drug device .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Polyps</keyword>
	<keyword>Capsule endoscopy</keyword>
	<keyword>Colonoscopy</keyword>
</DOC>